Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8233178 | 0.83 | GSK3B (0.48) | LMNAMAPTKDM4EKMT2AALDH1A1 | |
| SCHEMBL9545039 | 0.82 | NPC1 (0.53) | LMNACYP1A2CYP3A4MAPTKDM4E | |
| SCHEMBL1221520 | 0.80 | MAPT (0.54) | LMNACYP1A2CYP3A4MAPTKDM4E | |
| SCHEMBL11831572 | 0.79 | LMNA (0.46) | LMNACYP1A2CYP3A4MAOAMAPT | |
| SCHEMBL10787656 | 0.79 | KMT2A (0.48) | LMNACYP1A2CYP3A4MAOAMAPT | |
| SCHEMBL10528940 | 0.77 | KDM4E (0.66) | LMNAMAPTKDM4EHIF1ASLC22A6 | |
| SCHEMBL10576344 | 0.75 | ADRB2 (0.53) | LMNACYP1A2CYP3A4MAOAMAPT | |
| Hydrochloric Acid SCHEMBL10576388 | 0.74 | ADRB2 (0.51) | LMNACYP1A2CYP3A4MAOAMAPT | |
| SCHEMBL29407939 | 0.73 | KDM4E (0.41) | MAPTKDM4EHIF1ASLC22A6SLC22A8 | |
| SCHEMBL8487007 | 0.73 | CA12 (0.46) | LMNAMAPTKDM4EKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928827-B1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS INC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8217073-B2 | Pyrrole derivatives as therapeutic compounds | MYREXIS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20100216862-A1 | Pyrrole Derivatives As Therapeutic Compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-7714022-B2 | Pyrrole derivatives as therapeutic compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| EP-1928827-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007038684-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216862-A1 | Pyrrole Derivatives As Therapeutic Compounds | APP, PSEN2, PSEN1 | LMNA 3387/4885CYP1A2 4794/4885CYP3A4 4841/4885 |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | APP, PSEN2, PSEN1 | LMNA 3387/4885CYP1A2 4794/4885CYP3A4 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.